Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 6/20 | 0.83 |
| ▸ | MEN1 | O00255 | 9/20 | 0.81 |
| ▸ | THRB | P10828 | 9/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.81 |
| ▸ | BLM | P54132 | 8/20 | 0.81 |
| ▸ | RECQL | P46063 | 7/20 | 0.81 |
| ▸ | BRCA1 | P38398 | 6/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.81 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.81 |
| ▸ | MAPT | P10636 | 6/20 | 0.81 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.81 |
| ▸ | USP2 | O75604 | 4/20 | 0.81 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.81 |
| ▸ | TOP2A | P11388 | 4/20 | 0.81 |
| ▸ | HTT | P42858 | 4/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.81 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.81 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL10703620 | 0.99 | S100A4 (0.82) | S100A4MEN1THRBKMT2ABLM | |
| SCHEMBL3763974 | 0.95 | S100A4 (0.84) | S100A4MEN1THRBKMT2ABLM | |
| SCHEMBL248564 | 0.94 | S100A4 (0.85) | S100A4MEN1THRBKMT2ABLM | |
| SCHEMBL22717046 | 0.94 | S100A4 (0.82) | S100A4MEN1THRBKMT2ABLM | |
| SCHEMBL15200953 | 0.94 | S100A4 (0.82) | S100A4MEN1THRBKMT2ABLM | |
| SCHEMBL319890 | 0.94 | S100A4 (0.84) | S100A4MEN1THRBKMT2ABLM | |
| Hydrochloric Acid SCHEMBL331063 | 0.94 | S100A4 (0.84) | S100A4MEN1THRBKMT2ABLM | |
| SCHEMBL11563422 | 0.94 | S100A4 (0.84) | S100A4MEN1THRBKMT2ABLM | |
| SCHEMBL14164316 | 0.94 | S100A4 (0.84) | S100A4MEN1THRBKMT2ABLM | |
| SCHEMBL13943294 | 0.94 | S100A4 (0.84) | S100A4MEN1THRBKMT2ABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0295119-A2 | 14-Chlorodaunomycin and process for the preparation of 14-chlorodaunomycin, and process for the preparation of (2\"R)-4'-0-tetrahydropyranyladriamycin | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1988-12-14 | — | — | EP | claimed |
| CN-106170303-B | Pass through the pro-drug of caspase activation | 法罗斯根有限公司 | 2019-10-25 | — | — | CN | disclosed |
| CN-106170303-A | By the prodrug of caspase activation | 法罗斯根有限公司 | 2016-11-30 | — | — | CN | disclosed |
| CN-101925365-B | Nanoparticles of therapeutically active substances with low water solubility | CENTRE NAT RECH SCIENT | 2013-03-06 | — | — | CN | disclosed |
| CN-101925365-A | Nanoparticles of therapeutically active substances with low water solubility | CENTRE NAT RECH SCIENT | 2010-12-22 | — | — | CN | disclosed |
| US-20100035799-A1 | METHOD FOR THE SYNTHESIS OF ANTHRACYCLINE-PEPTIDE CONJUGATES | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2010-02-11 | — | — | US | disclosed |
| US-20050239688-A1 | Method for the synthesis of anthracycline-peptide conjugates | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2005-10-27 | — | — | US | disclosed |
| EP-1525002-A1 | METHOD FOR THE SYNTHESIS OF ANTHRACYCLINE-PEPTIDE CONJUGATES | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2005-04-27 | — | — | EP | disclosed |
| WO-2004011033-A1 | METHOD FOR THE SYNTHESIS OF ANTHRACYCLINE-PEPTIDE CONJUGATES | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2004-02-05 | — | — | WO | disclosed |
| CN-1045621-C | Immunoglobulin conjugates | ERBA FARMITALIA (IT) | 1999-10-13 | — | — | CN | disclosed |
| US-5798097-A | Immunogobulin conjugates | PHARMACIA & UPJOHN S.P.A. (IT) | 1998-08-25 | — | — | US | disclosed |
| EP-0358161-A2 | Novel anthracycline derivatives and process for production thereof | SANRAKU INCORPORATED (JP) | 1990-03-14 | — | — | EP | disclosed |
| EP-0295119-A2 | 14-Chlorodaunomycin and process for the preparation of 14-chlorodaunomycin, and process for the preparation of (2\"R)-4'-0-tetrahydropyranyladriamycin | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1988-12-14 | — | — | EP | disclosed |
| CN-88101810-A | IMMUNOGLOBULIN CONJUGATES | — | 1988-11-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035799-A1 | METHOD FOR THE SYNTHESIS OF ANTHRACYCLINE-PEPTIDE CONJUGATES | C9, DOHH, THOP1 | S100A4 3455/4885MEN1 2035/4885THRB 161/4885 |
| US-20050239688-A1 | Method for the synthesis of anthracycline-peptide conjugates | C9, DOHH, THOP1 | S100A4 3455/4885MEN1 2035/4885THRB 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.